A Comparative Study of the Efficacy of Atorvastatin Vs Rosuvastatin in Patients with Dyslipidemia Attending Tertiary Care Teaching Hospital
International Journal of Current Pharmaceutical Review and Research · 30.04.2026 · 18 (04)
DOI: 10.25258/ijcpr.18.4.197 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.04.2026. Verfasst von Ajit Kishor und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Dyslipidemia is a significant and modifiable risk factor for cardiovascular diseases with high low-density lipoprotein (LDL), elevated triglycerides (TG) levels, or low high-density lipoprotein (HDL). It is involved in atherosclerosis, coronary heart disease and stroke. Statins remain the first line pharmacological treatment, as they block HMG-CoA reductase resulting in decreased hepatic cholesterol synthesis and LDL receptor activity. Atorvastatin and Rosuvastatin are the most commonly prescribed statins for lipid control.
Methods
This prospective, randomised, open-label comparative study carried out over 1 year (December 2021-December 2022). A hundred patients with dyslipidaemia were randomly divided into two groups (n=50). Group A was given Atorvastatin 20 mg once daily, while Group B received Rosuvastatin 10 mg once daily for a period of 12 weeks. Fasting lipids were measured at baseline and after 12 weeks. Values of p < 0.05 were considered statistically significant.
Results
There was a significant improvement of lipids in both groups (p < 0.001). Reduction of LDL was by 17.78% with Atorvastatin and 19.26% with Rosuvastatin respectively. HDL was 5.54% higher and 9.13% respectively. The levels of TG were reduced by 11.50% and 13.96%. Rosuvastatin had a marginally superior effect on lipid reduction.
Conclusion
Both Atorvastatin and Rosuvastatin are effective with good tolerability in treatment of dyslipidemia. Rosuvastatin showed small advantage in LDL lowering and HDL improvements compared to Atorvastatin, which remains a cost-effective option for everyday clinical application.
Zitieren
APA
Kishor, A., Fatima, N., Seth, R. N., & Sinha, K. K. (2026). A Comparative Study of the Efficacy of Atorvastatin Vs Rosuvastatin in Patients with Dyslipidemia Attending Tertiary Care Teaching Hospital. International Journal of Current Pharmaceutical Review and Research, 18(04). https://doi.org/10.25258/ijcpr.18.4.197
Vancouver
Kishor A, Fatima N, Seth RN, Sinha KK. A Comparative Study of the Efficacy of Atorvastatin Vs Rosuvastatin in Patients with Dyslipidemia Attending Tertiary Care Teaching Hospital. International Journal of Current Pharmaceutical Review and Research. 2026;18(04). doi:10.25258/ijcpr.18.4.197
BibTeX
@article{Kishor2026,
author = {Kishor, Ajit and Fatima, Neha and Seth, Raj Narayan and Sinha, Keshav Kumar},
title = {A Comparative Study of the Efficacy of Atorvastatin Vs Rosuvastatin in Patients with Dyslipidemia Attending Tertiary Care Teaching Hospital},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {04},
doi = {10.25258/ijcpr.18.4.197}
}
EUVIMED